Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CELSR2 Antibody, Novus Biologicals™

Rabbit Polyclonal Antibody
Supplier: Novus Biologicals NBP185712
Description
CELSR2 Polyclonal specifically detects CELSR2 in Human samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.Specifications
CELSR2 | |
Polyclonal | |
Immunohistochemistry, Immunohistochemistry-Paraffin 1:20 - 1:50 | |
cadherin EGF LAG seven-pass G-type receptor 2, Cadherin family member 10, cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog, Drosophila), CDHF10FLJ34118, EGFL2FLJ45143, EGF-like protein 2, EGF-like-domain, multiple 2, epidermal growth factor-like 2, Epidermal growth factor-like protein 2, Flamingo homolog 3, Flamingo1, FLJ45845, KIAA0279FLJ42737, MEGF3cadherin, EGF LAG seven-pass G-type receptor 2, flamingo (Drosophila) homolog, Multiple EGF-like domains protein 3, multiple epidermal growth factor-like domains 3, Multiple epidermal growth factor-like domains protein 3 | |
Rabbit | |
Affinity Purified | |
RUO | |
Primary | |
Specificity of antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins. | |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
Immunohistochemistry, Immunohistochemistry (Paraffin) | |
Unconjugated | |
PBS (pH 7.2) and 40% Glycerol with 0.02% Sodium Azide | |
CELSR2 | |
This antibody was developed against Recombinant Protein corresponding to amino acids:SATQDVHFTENLLRVGSALLDTANKRHWELIQQTEGGTAWLLQHYEAYASALAQNMRHTYLSPFTIVTPNIVISVVRLDKGNFAGAKLPRYEALRGEQPPDLETTVILPESVFRETPPVVRPAGPGEAQEPEELARRQRRHPELSQ | |
0.1 mL | |
GPCR, Growth and Development, Neuronal Cell Markers | |
1952 | |
Human | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction